D6068

N-[4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenyl]benzamide hydrochloride

≥98% (HPLC), solid

• Synonim(y): 4-(4′-Benzamidoanilino)-6,7-dimethoxyquinazoline hydrochloride, Aurora Kinase Inhibitor II
• Wzór empiryczny (zapis Hilla): C₂₃H₂₀N₄O₃ · HCl
• Numer CAS: 179247-42-8
• Masa cząsteczkowa: 436.89
• NACRES: NA.77
• PubChem Substance ID: 24724466
• UNSPSC Code: 12352200
• MDL number: MFCD09265252
• Assay: ≥98% (HPLC)
• Form: solid

Właściwości

• assay: ≥98% (HPLC)
• form: solid
• color: yellow
• solubility: H₂O: <2 mg/mL, DMSO: ~2.4 mg/mL (with warming up to 60°C for 1 minute)
• originator: AstraZeneca
• storage temp.: 2-8°C
• SMILES string: Cl.COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC
• InChI: 1S/C23H20N4O3.ClH/c1-29-20-12-18-19(13-21(20)30-2)24-14-25-22(18)26-16-8-10-17(11-9-16)27-23(28)15-6-4-3-5-7-15;/h3-14H,1-2H3,(H,27,28)(H,24,25,26);1H
• InChI key: OQCLKJREASBKNO-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

Aurora Kinase Inhibitor

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• Hazard Classifications: Acute Tox. 4 Oral
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves